News | Cath Lab | October 27, 2016

Better Prognosis for Some PCI Patients When Operators Perform More Procedures

Patients needing more complex PCIs have better outcomes, according to Chinese study

PCI, operator volume, China study, JACC, outcomes

October 27, 2016 — Volume matters when it comes to who does certain procedures to removing heart-attack causing blockages from arteries, according to a new study published recently in JACC: Cardiovascular Interventions.

Researchers in China found patients undergoing left main coronary artery percutaneous coronary intervention (PCI) had better outcomes when the procedure was performed by experienced, high-volume operators — even though the patients treated by the experienced operators tended to have more complex and extensive heart disease. Left-main PCI can be used to treat patients with advanced coronary artery disease. In this procedure, a drug-eluting stent is placed in the left main coronary artery to open the blockage. The technique is minimally invasive and has been associated with fewer complications, short hospital stays and quicker recovery time than coronary artery bypass graft (CABG) surgery.

The researchers examined the records of 1,948 patients who underwent left-main PCI between January 2004 and December 2011, with 25 operators performing the procedure. Of those patients, 1,422 (73 percent) were treated by seven experienced, high-volume operators and 526 (27 percent) patients were treated by 18 less experienced, low-volume operators. High-volume operators performed a mean of 25 left-main PCIs per year, while low-volume operators performed a mean of four left-main PCIs per year. 

Patients treated by high-volume operators had better short- and long-term outcomes. Death within 30 days was 0.6 percent with high-volume operators and 2.1 percent with low-volume operators. There was no significant difference in rates of heart attack, and stroke over the same time period were lower in patients treated by high-volume operators. Patients of high-volume operators also had lower risks of cardiac death and all-cause mortality, as well as a trend toward a decreased risk of stent thrombosis.

After three years, patients treated by experienced, high-volume operators experienced a significantly lower risk of cardiac death.

These trends were observed even though patients who underwent left-main PCI with a high-volume operator had more extensive coronary artery disease and underwent more technically complex procedures. High-volume operators were also more likely to use first-generation, rather than superior second-generation, drug-eluting stents.

This is the first study to conclusively demonstrate that operator experience impacts the prognosis of patients who undergo high-risk PCI.

“Our findings suggest that high-risk and complex procedures, such as left-main PCI, should be reserved to a limited number of experienced operators in order to achieve the best outcomes,” said Yuejin Yang, M.D., from the department of cardiology at Fu Wai Hospital in Beijing and an author of the study. “Alternatively, less experienced operators could perform left-main PCI under the close supervision and mentorship of an experienced operator until they acquire sufficient skill and technique to become independent.”

In an editorial comment accompanying the study, Ralph G. Brindis, M.D., MPH, MACC, and Gregory J. Dehmer, M.D., MACC, examined data from the American College of Cardiology’s (ACC) National Cardiovascular Data Registry’s (NCDR) CathPCI Registry to determine the  amount of left-main PCI’s performed by high- and low-volume operators in the United States. They found that for left-main PCIs performed between April 2015 and March 2016, only 1 percent of operators would be considered high-volume based on the study’s criteria of having performed at least 15 left-main PCI’s per year for at least three consecutive years. Additionally, these operators performed only 8.4 percent of these annual procedures in the United States.

“These numbers are a stark contrast compared with the results of the study by Yang and colleagues and perhaps should be a wake-up call to the interventional community,” Brindis and Dehmer said. “The concept of a ‘Center of Excellence’ has been widely promoted and, frankly, overused to the point it now has little meaning. The study findings show that a ‘Center of Excellence’ for left-main PCI should be one with experienced, high-volume operators that can demonstrate good outcomes.”

Related NCDR CathPCI Registry articles:

• Radial Access, Same-Day Cardiac Procedure Could Save $300 Million Annually

• New Report Highlights National Trends in Heart Disease Treatments

• Study Finds Significant Variability in Doctors' Angioplasty Death Rates

 

For more information: www.jacc.org

Related Content

Bivalirudin exhibited an improvement in 30-day all-cause mortality when injected post PCI.
News | Antiplatelet and Anticoagulation Therapies| August 16, 2017
August 16, 2017 — A study has examined the efficacies of various post-percutaneous coronary intervention (PCI) bivali
CMS considers eliminating cardiac bundled payments.
Feature | Business| August 16, 2017 | Dave Fornell
August 16, 2017 — The Centers for Medicare and Medicaid Services (CMS) announced a proposed rule to reduce the number
ESC 2017 late breaking trial hot line study presentations.
News | Clinical Study| August 16, 2017
Aug. 16, 2017 – The European Society of Cardiology (ESC) Congress 2017 includes several Hot Line Late-breaking Clinic
News | Drug-Eluting Balloons| August 15, 2017
Surmodics Inc. announced receipt of an investigational device exemption (IDE) from the U.S. Food and Drug...
The Vascular Dynamics MobiusHD device enhances the carotid baroreceptors to reduce resistant hypertension.
News | Hypertension| August 15, 2017
Aug. 15, 2017 — The U.S. Food and Drug Administration (FDA) has approved the Vascular Dynamics Inc.
Abbott Initiates First Clinical Trial of Clip-Based Tricuspid Repair System
News | Heart Valve Technology| August 09, 2017
Abbott announced that the first patient has been enrolled in a clinical study to evaluate a minimally invasive clip-...
Four Blue Cross Blue Shield Companies Issue Positive Medical Policies on HeartFlow FFRct Analysis
News | FFR Catheters| August 09, 2017
HeartFlow Inc. announced that four Blue Cross Blue Shield companies have each issued a positive medical policy for the...
Ra Medical Systems Granted Broad Patent for DABRA Catheter
News | Peripheral Artery Disease (PAD)| August 09, 2017
August 9, 2017 — Ra Medical Systems announced that the United States Patent and Trademark Office (USPTO) has granted
Overlay Init